JP2025504519A - Ｓａｒｓ－ｃｏｖ－２に起因する感染症の予防および／または処置における使用のための化合物 - Google Patents

Ｓａｒｓ－ｃｏｖ－２に起因する感染症の予防および／または処置における使用のための化合物 Download PDF

Info

Publication number
JP2025504519A
JP2025504519A JP2024543838A JP2024543838A JP2025504519A JP 2025504519 A JP2025504519 A JP 2025504519A JP 2024543838 A JP2024543838 A JP 2024543838A JP 2024543838 A JP2024543838 A JP 2024543838A JP 2025504519 A JP2025504519 A JP 2025504519A
Authority
JP
Japan
Prior art keywords
cov
sars
oph
treatment
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504519A5 (https=
Inventor
ラフォルジュ，ミレイユ
グレッセン，ピエール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Cite filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2025504519A publication Critical patent/JP2025504519A/ja
Publication of JP2025504519A5 publication Critical patent/JP2025504519A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2024543838A 2022-01-24 2023-01-19 Ｓａｒｓ－ｃｏｖ－２に起因する感染症の予防および／または処置における使用のための化合物 Pending JP2025504519A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305072.5 2022-01-24
EP22305072 2022-01-24
PCT/EP2023/051296 WO2023139182A1 (en) 2022-01-24 2023-01-19 Compound for use in preventing and/or treating an infection caused by sars-cov-2

Publications (2)

Publication Number Publication Date
JP2025504519A true JP2025504519A (ja) 2025-02-12
JP2025504519A5 JP2025504519A5 (https=) 2026-01-26

Family

ID=80446266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543838A Pending JP2025504519A (ja) 2022-01-24 2023-01-19 Ｓａｒｓ－ｃｏｖ－２に起因する感染症の予防および／または処置における使用のための化合物

Country Status (6)

Country Link
US (1) US20250099530A1 (https=)
EP (1) EP4469073A1 (https=)
JP (1) JP2025504519A (https=)
KR (1) KR20240139056A (https=)
CN (1) CN119072326A (https=)
WO (1) WO2023139182A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2923160B1 (fr) 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
WO2021228846A1 (en) 2020-05-11 2021-11-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compound for preventing or treating a viral infection
WO2022008597A1 (en) * 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022123062A1 (en) * 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Also Published As

Publication number Publication date
EP4469073A1 (en) 2024-12-04
WO2023139182A1 (en) 2023-07-27
CN119072326A (zh) 2024-12-03
US20250099530A1 (en) 2025-03-27
KR20240139056A (ko) 2024-09-20

Similar Documents

Publication Publication Date Title
EA022303B1 (ru) Комбинации ингибиторов вируса гепатита с
Li et al. Antiviral activity of arbidol hydrochloride against herpes simplex virus I in vitro and in vivo
US20110046150A1 (en) Use of n--4-(3-pyridyl)-2-pyridine-amine for the treatment of pulmonary hypertension
WO2004067006A1 (en) Combination of a pde iv inhibitor and a tnf-alpha antagonist
EP3132803B1 (en) Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
IL237119A (en) Heterocyclic carboxamides for the treatment of viral diseases
JP4814799B2 (ja) トランスに相補されたゲノム欠損を有する呼吸器合胞体ウイルス
JP2025504519A (ja) Ｓａｒｓ－ｃｏｖ－２に起因する感染症の予防および／または処置における使用のための化合物
KR20230048517A (ko) 베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법
KR20230121767A (ko) Covid-19의 예방 및 치료를 위한 디펜히드라민 및 락토페린
WO2022157327A1 (en) Lonafarnib for use in the treatment of viral infections
CN104411308B (zh) 通过给予某些合成化合物治疗阿尔茨海默病的方法
EA038527B1 (ru) Способ лечения респираторного заболевания или состояния, композиции и наборы, содержащие двойной ингибитор киназ pi3k дельта-гамма и кортикостероид
AU2017210921B2 (en) Composition and combined medication method for treating enterovirus infection
US10517917B2 (en) Compositions and methods for preventing or treating pulmonary hypertension
CN115666550A (zh) 用于预防和/或治疗冠状病毒的半胱氨酸蛋白酶抑制剂
WO2021204814A1 (en) Nachr, such as nicotine, for use in the prevention and the treatment of covid-19 disease
KR102777596B1 (ko) 스트레스 과립 형성 억제제를 유효성분으로 포함하는 결핵의 예방 또는 치료용 약학 조성물
US12569495B2 (en) Inhibitors of porcine reproductive and respiratory syndrome virus
TWI764284B (zh) 使用喹啉化合物來對抗冠狀病毒感染的方法
EP4151214A1 (en) Rimegepant for treatment of human coronavirus infection
EP3900723A1 (en) Nachr, such as nicotine, for use in the prevention and the treatment of covid-19 disease
EP3892274A1 (en) Nicotine for the prevention and treatment of covid-19 disease
Parveen et al. Respiratory syncytial virus (RSV): prevention and antiviral therapeutic strategies
CN121401262A (zh) Ppm1a抑制剂在抗rna病毒中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260116